R2 Inhibitors

R2 (RRM2) inhibitors comprise a diverse array of compounds that effectively disrupt the enzyme's activity, playing a crucial role in DNA synthesis. Direct inhibitors such as Hydroxyurea and Triapine target R2 by specific mechanisms: Hydroxyurea impedes R2's function by scavenging essential tyrosyl radicals, directly inhibiting the ribonucleotide reductase activity. Triapine acts by chelating iron within R2's active site, blocking its enzymatic action. These direct inhibitory actions are significant as they prevent R2 from fulfilling its role in DNA synthesis, showcasing the potential of targeting specific molecular components to disrupt critical enzymatic processes.

In contrast, nucleoside or nucleotide analogs such as 2'-Deoxy-2',2'-difluorocytidine, Fludarabine, 2-Chloro-2′-deoxyadenosine, Decitabine, Capecitabine, Fluorouracil, 1-β-D-Arabinofuranosylcytosine, and Clofarabine indirectly affect R2. These compounds, upon incorporation into DNA, interfere with normal DNA synthesis and repair mechanisms, disrupting the cellular functions dependent on R2. Additionally, compounds like Cisplatin and Oxaliplatin indirectly inhibit R2 by inducing DNA damage and initiating DNA repair pathways, which subsequently impact DNA synthesis. These indirect methods of inhibiting R2 highlight the interconnected nature of cellular pathways and the possibility of targeting ancillary pathways to modulate the activity of key enzymes like R2. The varied mechanisms employed by these inhibitors, ranging from direct enzymatic disruption to interference in DNA synthesis and repair, underscore the complex regulation of R2 and its significance in cellular proliferation and DNA replication processes.